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 Text 
From the authors: 
We thank Guan and colleagues for highlighting important additional research priorities for 
bronchiectasis in China. The EMBARC research priorities “roadmap” published in the ERJ was 
specifically developed to address the issue of research priorities from the point of view of European 
experts, and with this in mind it is important to consider how these priorities may be different across 
different healthcare systems.(1,2)  
 
Bronchiectasis appears to be very different across the world. In addition to the different 
characteristics observed in China compared to Europe, (3,4)] the emerging Indian Bronchiectasis 
Registry, as part of the EMBARC network, has reported a high rate of post-TB bronchiectasis and 
bronchiectasis related to COPD. A further research priority is therefore to understand the 
prevalence, impact and outcomes of bronchiectasis following TB infection.  
In the United States bronchiectasis registry, 63.5% of patients had a history of pulmonary NTM 
disease, an aetiology or complication seen much less frequently in Europe.(3) We may therefore 
add from a North American perspective, a key priority to identify the optimal treatment for NTM 
infections as well as understanding the susceptibility factors and disease characteristics associated 
with NTM infection.(5,6) While many of the research priorities for colleagues in Australasia would 
be similar to those of Europe, we might add priorities to understanding the burden of disease and 
aetiology in indigenous populations.(7)  
Therefore it is clear that across the world, patient populations and therefore research priorities may 
be different. Nevertheless, the desire to improve patient outcomes and to find evidence for new 
treatments remains the same.(8) 
It is in this spirit that an international collaborator effort for bronchiectasis is now well advanced. 
The EMBARC network (www.bronchiectasis.eu) is closely aligned with research efforts in many 
individual European countries,(9) but most importantly is collaborating closely with international 
bronchiectasis networks. The United States Bronchiectasis Research Registry began data collection 
in 2008 across 13 centres and incorporates data collection for bronchiectasis bronchiectasis and 
NTM disease. The Australian Bronchiectasis Registry, under the auspices of the Australian Lung 
Foundation has recently begun recruitment and has the unique feature of collecting data on 
children. EMBARC India, The Indian bronchiectasis registry, is far advanced with more than 500 
patients enrolled at the time of writing from more than 33 centres. Emerging bronchiectasis 
research programmes are in development in other countries including Latin America, Sri Lanka and 
South Africa.  
An important symbol of this new international consortium of bronchiectasis researchers was the 
first World Bronchiectasis Conference in Hannover, Germany in July 2016 (WBC; http://world-
bronchiectasis-conference.com). This event saw the participation of more than 300 delegates from 
around the world who met to discuss clinical and translational aspects of bronchiectasis under the 
auspices of the European Respiratory Society, EMBARC and PROGNOSIS. In the wake of this major 
success, the 2nd WBC has been organized in Milan, Italy, in July 2017, with a special focus of 
bronchiectasis clinical trials and pulmonary NTM.  
 
We invite all those with an interest in bronchiectasis to participate in these international 
collaborative efforts. Specific objectives of our collaboration are: 1) To merge different 
bronchiectasis registries on a common platform with shared definitions to allow comparative global 
studies and generalizable research findings; 2) To identify integrate and compare research needs in 
the field; 3) To share infrastructures and competencies in order to design and conduct high-quality 
trials according to a common roadmap; 4) To plan educational policies to increase the disease 
awareness and enlarge the group of experts interested in bronchiectasis (10); 5) To facilitate the 
interaction between national groups of patients suffering from this disease. This integrated and 
multinational approach, we believe, is the way to achieve progress not just in one part of the world, 
but for the disease globally.   
We look forward to working with all of our international colleagues who share the one and only 
core priority- to improve the quality of life for patients with bronchiectasis.  
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